Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DexaBEAM
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
DexaBEAM is a multi-agent chemotherapy regimen used primarily as salvage therapy for relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. The regimen consists of five drugs: dexamethasone, carmustine (BCNU), etoposide, cytarabine (Ara-C), and melphalan. Each component has a distinct mechanism of action targeting cancer cells through different pathways: - Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects. - Carmustine is an alkylating agent that crosslinks DNA, inhibiting replication. - Etoposide inhibits topoisomerase II, leading to DNA strand breaks. - Cytarabine is an antimetabolite that interferes with DNA synthesis. - Melphalan is another alkylating agent causing DNA crosslinking. DexaBEAM has demonstrated efficacy as salvage therapy in patients who have failed prior multi-drug chemotherapy regimens for Hodgkin's disease[7]. It produces high response rates but carries significant hematologic toxicity, particularly granulocytopenia and thrombocytopenia.
- Brand names
- DexaBEAM
- Other names
- Dexa-BEAM
02
Targets
GR (Glucocorticoid receptor)DNA polymerase familyTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on DexaBEAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DexaBEAM.